chemXplore tracks 50 projects in Canada, of which 31 are active.
Of the active ones, 21 new construction, 9 expansion and 1 revamp / retrofit.
8 active projects carry no start-up date yet. The dates themselves, per project, are for subscribers.
Transaction supports maturation toward an early‑2027 investment decision; operator retains 70% and FPSO-based development in the Flemish Pass continues.
Rina‑S 120 mg/m² Q3W achieved 45.9% ORR and 12.1‑month median DOR in 109 platinum‑resistant ovarian cancer patients; activity seen across FRα expression levels.
Joins the national bioenergy body and signs an MoU to explore bioSAF from captured sugarcane waste in Queensland; links to international scale-up pipeline.
MRI‑PDFF subanalysis (n=55) found mean liver fat fell from 8.8% to 3.1% at week 72; 88.5% with baseline liver fat >5% reached <5%.
Rapid, significant relief in skin clearance, itch, pain and patient satisfaction versus placebo; consistent safety and fewer patients required rescue medication.
fMRI shows reduced ‘food noise’ and cravings; trials report major weight loss, reductions in abdominal/liver/pancreas fat and preliminary bone‑marker reassurance.
Notice to Proceed issued for LNG Canada Phase 2 after FID; contract mainly lump-sum with some cost-plus; JGC to recognise US$7.5bn in fiscal 2026 after FEED update.
Notice to proceed issued; US$7.5bn share to be recognized in Q3 FY2026; Phase 2 adds one storage tank and two trains, doubling output to ~28 Mtpa.
Phase 2 will double Kitimat LNG output to 28 mtpa; Shell’s 40% stake adds nearly 6 mtpa, with commercial operations targeted in the early 2030s.
FDA accepted the sNDA and granted Priority Review for Lynkuet to treat moderate to severe vasomotor symptoms in women on endocrine therapy for HR+ breast cancer.
active / all projects
